Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sang Haak | - |
dc.contributor.author | Lee, Jongmin | - |
dc.contributor.author | Yoo, Kwang Ha | - |
dc.contributor.author | Uh, Soo-Taek | - |
dc.contributor.author | Park, Myung Jae | - |
dc.contributor.author | Lee, Sang Yeub | - |
dc.contributor.author | Kim, Jae Yeol | - |
dc.contributor.author | Kim, Deog Kyeom | - |
dc.contributor.author | Kim, Seung Joon | - |
dc.contributor.author | Lee, Kwan Ho | - |
dc.contributor.author | Yoo, Chul-Gyu | - |
dc.date.accessioned | 2021-09-04T10:51:09Z | - |
dc.date.available | 2021-09-04T10:51:09Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2015-11 | - |
dc.identifier.issn | 1323-7799 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/91964 | - |
dc.description.abstract | Background and objective: Aclidinium bromide ('aclidinium') is a novel, inhaled long-acting muscarinic antagonist. Therapeutic effects of aclidinium on chronic obstructive pulmonary disease (COPD) have been demonstrated in Caucasian populations in several clinical trials. This was a randomized, double-blind, multi-centre phase-3 clinical trial to evaluate the efficacy and safety of aclidinium in a Korean population. Methods: A total of 263 Korean patients with moderate-to-severe COPD were randomized to receive aclidinium (400 mu g, bd) (Genuai) or placebo via a dry-powder inhaler. The primary end point was change in trough forced expiratory volume in one second (FEV1) at 12 weeks. Other lung function measurements, COPD exacerbation, health status (St George's Respiratory Questionnaire (SGRQ), dyspnoea (Transition Dyspnea Index (TDI) and safety were assessed throughout the study period. Results: A significant improvement in trough FEV1 from baseline was shown with aclidinium compared with the placebo (0.126 L, P < 0.0001). Significant improvements were also demonstrated in peak FEV1 (0.190 L, P < 0.0001), SGRQ and TDI. Furthermore, aclidinium significantly reduced the prevalence of exacerbations (aclidinium, 5.4%; placebo, 15.6%, P < 0.05), and the duration of exacerbations was shorter compared with placebo (rate ratio: 0.27; P < 0.05). Aclidinium (400 mu g) was well tolerated and the prevalence of adverse events was comparable with the placebo. Conclusions: Inhaled aclidinium (400 mu g) was shown to be safe and efficacious in Korean patients with moderate-to-severe COPD. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.subject | OBSTRUCTIVE PULMONARY-DISEASE | - |
dc.subject | ADMINISTERED TWICE | - |
dc.subject | MU-G | - |
dc.subject | PHARMACOKINETICS | - |
dc.subject | TIOTROPIUM | - |
dc.subject | PLACEBO | - |
dc.subject | 12-WEEK | - |
dc.title | Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Sang Yeub | - |
dc.identifier.doi | 10.1111/resp.12641 | - |
dc.identifier.scopusid | 2-s2.0-84945455873 | - |
dc.identifier.wosid | 000365411900011 | - |
dc.identifier.bibliographicCitation | RESPIROLOGY, v.20, no.8, pp.1222 - 1228 | - |
dc.relation.isPartOf | RESPIROLOGY | - |
dc.citation.title | RESPIROLOGY | - |
dc.citation.volume | 20 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1222 | - |
dc.citation.endPage | 1228 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.subject.keywordPlus | OBSTRUCTIVE PULMONARY-DISEASE | - |
dc.subject.keywordPlus | ADMINISTERED TWICE | - |
dc.subject.keywordPlus | MU-G | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | TIOTROPIUM | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | 12-WEEK | - |
dc.subject.keywordAuthor | aclidinium bromide | - |
dc.subject.keywordAuthor | cholinergic antagonist | - |
dc.subject.keywordAuthor | chronic obstructive pulmonary disease | - |
dc.subject.keywordAuthor | safety | - |
dc.subject.keywordAuthor | treatment outcome | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.